RANCHO CORDOVA, Calif., Aug. 31, 2017 (GLOBE NEWSWIRE) — Cesca Therapeutics Inc. (NASDAQ:KOOL), a market leader in automated cell processing and point-of-care, autologous cell-based therapies, today announced that the Company will present at the CAR-TCR Summit 2017, which is being held September 6-7, 2017 at the Seaport Hotel & World Trade Center in Boston.
Jon Ellis, senior director of technical services at ThermoGenesis, Cesca’s device subsidiary, will deliver a spotlight presentation on ThermoGenesis’ automated CAR-T cell manufacturing capabilities on Thursday, September 7, 2017 at 10:40am ET during the “Tech Slam at the Innovation Hub.”
The CAR-TCR Summit brings together over 60 world-class speakers and more than 500 cell therapy experts in the only end-to-end conference dedicated to successfully bringing the next generation CAR-T & TCR cell immunotherapies to market. For more information, please visit http://car-tcr-summit.com.
About Cesca Therapeutics Inc.
Cesca is a leading regenerative medicine company that develops, commercializes and markets a range of automated technologies for cell-based therapeutics. Its device division, ThermoGenesis, provides a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology. Cesca is also leveraging its proprietary AutoXpress® technology platform to develop autologous stem cell-based therapies that address significant unmet needs in the vascular, cardiology and orthopedic markets.
Forward-Looking Statement
The statements contained herein may include statements of future expectations and other forward-looking statements that are based on management’s current views and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. A more complete description of risks that could cause actual events to differ from the outcomes predicted by Cesca Therapeutics’ forward-looking statements is set forth under the caption “Risk Factors” in Cesca Therapeutics’ annual report on Form 10-K and other reports it files with the Securities and Exchange Commission from time to time, and you should consider each of those factors when evaluating the forward-looking statements.
CONTACT: Company Contact: Cesca Therapeutics Inc. Wendy Samford 916-858-5191 ir@cescatherapeutics.com Investor Contact: Rx Communications Paula Schwartz 917-322-2216 pschwartz@rxir.com
